| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ADMA | Common Stock | Award | $0 | +557,728 | +25% | $0.000000 | 2,766,581 | 26 Feb 2024 | Direct | F1, F2, F3, F4 |
| holding | ADMA | Common Stock | 1,143,426 | 26 Feb 2024 | See Footnote | F5 | |||||
| holding | ADMA | Common Stock | 580,957 | 26 Feb 2024 | See Footnote | F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ADMA | Stock Option (right to buy) | Award | $0 | +870,950 | $0.000000 | 870,950 | 26 Feb 2024 | Common Stock | 870,950 | $5.40 | Direct | F7 |
| Id | Content |
|---|---|
| F1 | These shares represent restricted stock units ("RSUs") that will vest quarterly on each three-month anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date. |
| F2 | Includes, as of the transaction date, (i) 557,728 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 225,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 226,875 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into |
| F3 | (continued from footnote 2) common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,785 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each three-month anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting; |
| F4 | (continued from footnote 3) and (vi) 1,137,498 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. |
| F5 | These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth. |
| F6 | These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden. |
| F7 | The option vests over four years with 25% of the shares of Common Stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028 in accordance with the Plan. |